SGS has completed a Phase I trial of a new strain of influenza virus in healthy volunteers. The agent is approved for use as a challenge agent in studies demonstrating the early efficacy of influenza drugs and vaccines in healthy volunteers.   The study used a GMP-manufactured, non-hemagglutinating, wild-type strain of Influenza A H3N2 in humans at single, ascending titers to determine attack rate (AR), viral area under curve (vAUC) and symptoms following nasal inoculation. The First-in-Human ...